Related Experiment Videos
Pergolide-induced retroperitoneal fibrosis
1Department of Medicine for the Elderly, Rotherham District General Hospital, South Yorkshire, UK.
International Journal of Clinical Practice
|November 25, 2000
Abstract:
Retroperitoneal fibrosis is a rare complication of pergolide therapy. This complication can be easily missed, so it is essential to have a high index of suspicion. We describe a case of well controlled Parkinson's disease who presented with shortness of breath and oedema.
Insights
Retroperitoneal fibrosis is a rare side effect of pergolide, often missed in Parkinson's disease patients. Early suspicion is crucial for diagnosis in patients presenting with symptoms like edema.
Area of Science:
- Nephrology
- Neurology
- Pharmacology
Background:
- Pergolide is a dopamine agonist used for Parkinson's disease.
- Retroperitoneal fibrosis (RPF) is a rare but serious complication associated with certain medications.
- Early recognition of RPF is critical for patient outcomes.
Observation:
- A patient with well-controlled Parkinson's disease developed shortness of breath and edema.
- These symptoms were indicative of a potential underlying complication.
- The patient was undergoing therapy with pergolide.
Findings:
- The patient's presentation was consistent with retroperitoneal fibrosis.
- This condition was a rare complication of pergolide treatment.
- A high index of suspicion is necessary to diagnose this easily missed complication.
Implications:
- This case highlights the importance of considering medication side effects in patients with atypical presentations.
- Increased awareness of pergolide-induced RPF can lead to earlier diagnosis and intervention.
- Further research into the mechanisms and risk factors for drug-induced RPF is warranted.